NASDAQ:VSTM - Verastem Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.13 -0.03 (-1.39 %)
(As of 04/26/2019 12:12 PM ET)
Previous Close$2.16
Today's Range$2.11 - $2.17
52-Week Range$2.08 - $10.35
Volume9,773 shs
Average Volume2.66 million shs
Market Capitalization$157.36 million
P/E RatioN/A
Dividend YieldN/A
Beta3.03
Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being investigated in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), mesothelioma, and other solid tumors. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited. The company was founded in 2010 and is headquartered in Needham, Massachusetts.

Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VSTM
CUSIP92337C10
Phone781-292-4200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.72 million
Book Value$1.68 per share

Profitability

Net Income$-72,430,000.00

Miscellaneous

Employees169
Market Cap$157.36 million
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable

Verastem (NASDAQ:VSTM) Frequently Asked Questions

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

How were Verastem's earnings last quarter?

Verastem Inc (NASDAQ:VSTM) announced its quarterly earnings results on Tuesday, March, 12th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.60) by $0.23. The biopharmaceutical company earned $1.21 million during the quarter, compared to the consensus estimate of $5.56 million. View Verastem's Earnings History.

When is Verastem's next earnings date?

Verastem is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Verastem.

What price target have analysts set for VSTM?

7 brokers have issued 1 year price targets for Verastem's shares. Their forecasts range from $5.00 to $17.00. On average, they expect Verastem's share price to reach $12.1429 in the next year. This suggests a possible upside of 470.1% from the stock's current price. View Analyst Price Targets for Verastem.

What is the consensus analysts' recommendation for Verastem?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verastem.

Has Verastem been receiving favorable news coverage?

Media coverage about VSTM stock has been trending somewhat positive on Friday, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Verastem earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the near term.

Are investors shorting Verastem?

Verastem saw a drop in short interest in March. As of March 29th, there was short interest totalling 16,839,750 shares, a drop of 30.4% from the March 15th total of 24,185,220 shares. Based on an average trading volume of 2,899,002 shares, the days-to-cover ratio is presently 5.8 days. Currently, 24.8% of the company's stock are sold short. View Verastem's Current Options Chain.

Who are some of Verastem's key competitors?

What other stocks do shareholders of Verastem own?

Who are Verastem's key executives?

Verastem's management team includes the folowing people:
  • Mr. Robert Forrester, Pres, CEO & Director (Age 55)
  • Mr. Richard H. Aldrich Mba, Founder and Consultant (Age 65)
  • Dr. Robert A. Weinberg, Co-Founder and Chair of Scientific Advisory Board
  • Dr. Piyush B. Gupta, Co-Founder
  • Dr. Michelle Dipp, Co-Founder (Age 43)

Who are Verastem's major shareholders?

Verastem's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Howland Capital Management LLC (0.31%) and BNP Paribas Arbitrage SA (0.02%). Company insiders that own Verastem stock include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Robert Forrester, Steven H Bloom and Timothy J Barberich. View Institutional Ownership Trends for Verastem.

Which institutional investors are selling Verastem stock?

VSTM stock was sold by a variety of institutional investors in the last quarter, including Howland Capital Management LLC. View Insider Buying and Selling for Verastem.

Which institutional investors are buying Verastem stock?

VSTM stock was bought by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA. Company insiders that have bought Verastem stock in the last two years include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Robert Forrester, Steven H Bloom and Timothy J Barberich. View Insider Buying and Selling for Verastem.

How do I buy shares of Verastem?

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $2.13.

How big of a company is Verastem?

Verastem has a market capitalization of $157.36 million and generates $26.72 million in revenue each year. The biopharmaceutical company earns $-72,430,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Verastem employs 169 workers across the globe.

What is Verastem's official website?

The official website for Verastem is http://www.verastem.com.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected]


MarketBeat Community Rating for Verastem (NASDAQ VSTM)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  411 (Vote Outperform)
Underperform Votes:  306 (Vote Underperform)
Total Votes:  717
MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe VSTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/26/2019 by MarketBeat.com Staff

Featured Article: Risk Tolerance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel